только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 7 / 8
Страница 1 / 1

Список литературы

  1. Сardozo L., Staskin D. Textbook of female urology and urogynaecology. 2005. P. 183–227.
  2. Касян Г.Р., Куприянов Ю.А., Ходырева Л.А., Дударева А.А. Синдром гипер­активного МП в клинической практике врача-уролога. Методические рекомендации. 2019. № 13.
  3. Gormley E.A., Lightner D.J., Burgio K.L. et al. Diagnosis and treatment of overactive bladder (nonneurogenic) in adults: AUA/SUFU guideline. 2014.
  4. Minassian V. Urinary incontinence in women: variation in prevalence estimates and risk factors // Obstet. Gynecol. 2008. Vol. 111. P. 324–331.
  5. Milsom I., Abrams P., Cardozo L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study // BJU Int. 2001. Vol. 87. P. 760–766.
  6. Касян Г.Р., Гвоздев М.Ю., Коноплянников А.Г., Пушкарь Д.Ю. Недержание мочи у женщин. Методические рекомендации. М., 2017.
  7. Abrams P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society // Neurourol. Urodyn. 2002. Vol. 21. P. 167. https://pubmed.ncbi.nlm.nih.gov/11857671/.
  8. Maserejian N.N., Curto Т., Susan A. Reproductive history and progression of lower urinary tract symptoms in women: results from a population-based cohort study // Urology. 2014. P. 83.
  9. Coyne K.S., Sexton C.C., Vats V. et al. National community prevalence of overactive bladder in the United States stratified by sex and age // Urology. 2011. Vol. 77. P. 1081; Aránguiz-Ramírez J. et al. // Obstet. Gynecol. Res. 2022. DOI: 10.26502/ogr0107.
  10. Fontaine C., Papworth E., Pascoe J., Hashim H. Update on the management of overactive bladder // Ther. Adv. Urol. 2021. Vol. 31. DOI: 10.1177/17562872211039034. 
  11. Aránguiz-Ramírez J., Olivares-Tirado P., Castells-Oliveres X. Costs associated with Female Urinary Incontinence: an integrative review of the literature // Obstet. Gynecol. Res. 2022. Vol. 5. P. 325–333. DOI: 10.26502/ogr0107.
  12. Arnold J., McLeod N., Thani-Gasalam R. et al. Overactive bladder syndrome: management and treatment options // Aust. J. Gen. Pract. 2012. Vol. 41. P. 878–883; Haylen B.T., de Ridder D., Freeman R.M. et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction // Neurourol. Urodyn. 2010. Vol. 29. P. 4.
  13. Gormley E.A., Lightner D.J., Burgio K.L. et al. Diagnosis and treatment of overactive bladder (nonneurogenic) in adults. AUA/SUFU guideline. 2014.
  14. Minassian V. Urinary incontinence in women: variation in prevalence estimates and risk factors // Obstet. Gynecol. 2008. Vol. 111. P. 324–331.
  15. Bump R., Norton R. Epidemiology and natural history of pelvic floor dysfunction // Obstet. Gynecol. Clin. North. Am. 1998. Vol. 25. P. 723–746.
  16. Cardozo L., Staskin D. Pregnancy and childbirth. Textbook of female Urology and Urogynaecology, UK. 2002. P. 977–994.
  17. Wijma J., Weis A., Wolf B. Anatomical and functional changes in the lower urinary tract during pregnancy // Br. J. Obstet. Gynecol. 2001. Vol. 108. P. 726–732.
  18. Minassian V. Urinary incontinence in women: variation in prevalence estimates and risk factors // Obstet. Gynecol. 2008. Vol. 111. P. 324–331; Bump R., Norton R. Epidemiology and natural history of pelvic floor dysfunction // Obstet. Gynecol. Clin. North. Am. 1998. Vol. 25. P. 723–746.
  19. Cardozo L., Staskin D. Pregnancy and childbirth. Textbook of female Urology and Urogynaecology. UK, 2002. P. 977–994.
  20. Wijma J., Weis A., Wolf B. Anatomical and functional changes in the lower urinary tract during pregnancy // Br. J. Obstet. Gynecol. 2001. Vol. 108. P. 726–732.
  21. Rotveit G., Hunskaar S. Urinary incontinence and age at the first and last delivery: the Norwegian HUNT/EPINCONT study // Am. J. Obstet. Gynecol. 2006. Vol. 195. P. 433–438.
  22. Arjun K. Nambiar, Arlandis S., Bø K. et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence // Eur. Urol. 2022. Vol. 82. N. 1. P. 49–59. DOI: 10.1016/j.eururo.2022.01.045.
  23. Delgado J.L., Carmona F. et al. Genitourinary syndrome of menopause. The GENISSE study // Climacteric. 2018. № 21. Р. 167–173.
  24. Nappi R.E., Palacios S., Bruyniks N. et al. The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey // Menopause. 2019. № 26. Р. 485–491.
  25. Coyne K.S., Sexton C.C., Bell J.A. et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ ethnic group and age: results from OAB-POLL // Neurourol. Urodyn. 2013. Vol. 32. P. 230–237.
  26. American Urological Association. Overactive Bladder (OAB) guideline.
    https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline (2020, accessed 29 December 2020).
  27. European Association of Urology. EAU Guidelines: urinary incontinence.
    https://uroweb.org/guideline/urinary-incontinence/ (2020, accessed 29 December 2020).
  28. NICE Pathways. Managing overactive bladder in women. https://www.nice.org.uk/guidance/published?sp=on (2020, accessed 29 December 2020).
  29. Utian Wulf H., Archer David F., Bachmann Gloria A. et al. Estrogen and progestogen use in postmenopausal women: position statement of The North American Menopause Society // Journal of The North American Menopause Society. 2008. № 4. P. 584–603; Gebhardt J., Richard D., Barrett T. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women // Am. J. Obstet. Gynecol. 2001. P. 1325–1330.
  30. Truzzi J.C., Gomes C.M., Bezerra C.A. et al. Overactive bladder — 18 years —
    Part I // Int. Braz. J. Urol. 2016. Vol. 42. P. 188–198.
  31. Portman D.J., Gass M.L. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society // Menopause. 2014. Vol. 21. N. 10. P. 1063–1068. DOI: 10.1097/GME.0000000000000329. PMID: 25160739.
  32. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society // Menopause. 2020. Vol. 27. N. 9. P. 976–992; Nappi R.E., Palacios S., Bruyniks N. et al. The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey // Menopause. 2019. Vol. 26. N. 5. P. 485–491.
  33. Maris E. et al. Management of vulvovaginal atrophy: Physical therapies. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines // Gynecol. Obstet. Fertil. Senol. 2021. Vol. 49. N. 5. P. 414–419.
    DOI: 10.1016/j.gofs.2021.03.021 2468-7189/C.
  34. Lee S.R., Cho M.K., Cho Y.J. et al. The 2020 Menopausal Hormone Therapy Guidelines // J. Menopausal Med. 2020. Vol. 26. N. 2. P. 69–98.
  35. Srikrishna S., Robinson D., Cardozo L. et al. Management of overactive bladder syndrome // Postgrad. Med. J. 2007. Vol. 83. P. 481–486.
  36. Pelletier E.M., Vats V., Clemens J.Q. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder // Am. J. Manag. Care. 2009. Vol. 15. Suppl. 4. P. S108–S114.
  37. Abrams P., Kelleher C., Staskin D. et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony) // Eur. Urol. 2015. Vol. 67. P. 577–588.
  38. Yoshida M., Takeda M., Gotoh M. et al. Vibegron, a novel potent and selective â3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study // Eur. Urol. 2018. Vol. 73. P. 783–790.
  39. Lekskulchai O. et al. Is detrusor hypertrophy in women associate with voiding dysfunction? // Aust. N. Z. J. Obstet. Gynaecol. 2009. Vol. 49. P. 653.
    https://pubmed.ncbi.nlm.nih.gov/20070717/.
  40. Клинические рекомендации Российского общества урологов / Под ред. Ю.Г. Аляева. М., 2017.
  41. Brukhard F.C. et al. EAU guidelines on Urinary incontinence in adults. European Association of Urology. 2017.
  42. Клинические рекомендации «Недержание мочи». МЗ РФ. 2020.
  43. Madhu C. et al. How to use the pelvic organ prolapse quantification (POP‐Q) system? // Neurourology and urodynamics. 2018. Vol. 37. N. S6. P. S39–S43.
  44. Brukhard F.C. et al. EAU guidelines on Urinary incontinence in adults. European Association of Urology, 2017.
  45. Pushkar D.Y., Godunov B.N., Gvozdev M., Kasyan G.R. Complications of midurethral slings for treatment of stress urinary incontinence // Int. J. Gynaecol. Obstet. 2011. Vol. 113. N. 1. P. 54–57. DOI: 10.1016/j.ijgo.2010.10.024.
  46. Rosier P.F.W.M. et al. Committee 6. Urodynamic testing // Incontinence, 2017. Abrams P., Cardozo L., Wagg A., Wein A. Incontinence, 6th Edition. 2017. P. 599.
  47. NICE Guidance — Urinary incontinence and pelvic organ prolapse in women: management // BJU Int., 2019. Vol. 123. P. 777. https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.14763.
  48. van Leijsen S.A. et al. The correlation between clinical and urodynamic diagnosis in classifying the type of urinary incontinence in women. A systematic review of the literature // Neurourol. Urodyn. 2011. Vol. 30. P. 495.
  49. Abdel-Fattah M. et al. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms // Trials. 2021. Vol. 22. P. 745.
  50. Rachaneni S. et al. Does preoperative urodynamics improve outcomes for women undergoing surgery for stress urinary incontinence? A systematic review and meta-analysis // BJOG. 2015. Vol. 122. N. 8. https://pubmed.ncbi.nlm.nih.gov/25041381.
  51. Nager C.W. et al. A randomized trial of urodynamic testing before stress-incontinence surgery // N. Engl. J. Med. 2012. Vol. 366. P. 1987. https://pubmed.ncbi.nlm.nih.gov/22551104.
  52. Bo K. et al. Is pelvic floor muscle training effective for symptoms of overactive bladder in women? A systematic review // Physiotherapy. 2020. Vol. 106. P. 65. https://pubmed.ncbi.nlm.nih.gov/32026847/.
  53. Sand P.K. et al. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged >/=75 years) with overactive bladder syndrome // BJU Int. 2011. Vol. 107. P. 612; Wesnes K.A. et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg // Expert. Opin. Drug Saf. 2009. Vol. 8. P. 615.
  54. Guideline for Overactive Bladder in Females Female Continence Clinic. 2021.
  55. Nishtala P.S., Salahudeen M.S., Hilmer S.N. Anticholinergics: theoretical and clinical overview // Expert Opin. on Drug Saf. 2016. Vol. 15. N. 6. P. 753–768. DOI: 10.1517/14740338.2016.1165664; Durán C.E. et al. Systematic review of anticholinergic risk scales in older adults // Eur. J. Clin. Pharmacol. 2013. Vol. 69. P. 1485–1496. DOI: 10.1007/s00228-013-1499-3.
  56. Burkhard F.C. et. al. EAU Guidelines on Urinary Incontinence. 2020.
    www.uroweb.org.
  57. Wagg A. et al. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis // Am. J. Geriatr. Pharmacother. 2006. Vol. 4. P. 14. https://pubmed.ncbi.nlm.nih.gov/16730617/.
  58. Mirabegron (Betmiga.nlm.nih.gov/16730617/ov/16730617/" a pooled analysis. ascular and cardiac events [Internet]). GOV.UK. https://www.gov.uk/drug-safety-update/mirabegronbetmiga-risk-of-severe-hypertension-andassociated-cerebrovascular-and-cardiac-events (2021, accessed 23 January 2021).
  59. Sant M., Galea P., Brincat M.P. A comparative study between oestrogen replacement therapy, anticholinergic treatment and a combination of both in the management of detrusor instability in postmenopausal women // Book of Abstracts, The 10th World Congress on the menopause. Berlin, 2002. NICE Urinary incontinence in women: management clinical guideline niec.org.uk/guidance/cg171 (2015).
  60. Pitkin J.; on behalf of the British Menopause Society medical advisory council. BMS — Consensus statement // Post. Repros. Health. 2018. Vol. 24. N. 3.
    P. 133–138. DOI: 10.1177/2053369118795349.
  61. Cody J.D. et al. Oestrogen therapy for urinary incontinence in post-menopausal women // Cochrane Database Syst. Rev. 2012. Vol. 10. P. CD001405.
    https://pubmed.ncbi.nlm.nih.gov/23076892
  62. Lyytinen H. et al. Breast cancer risk in postmenopausal women using estrogen-only therapy // Obstet. Gynecol. 2006. Vol. 108. P. 1354. https://pubmed.ncbi.nlm.nih.gov/17138766/.
  63. Yumru A.E. et al. The use of local 17beta-oestradiol treatment for improving vaginal symptoms associated with post-menopausal oestrogen deficiency // J. Int. Med. Res. 2009. Vol. 37. P. 198. https://pubmed.ncbi.nlm.nih.gov/19215691/239.
  64. Mostafaei H. et al. Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis // Eur. Urol. Focus. 2022. Vol. 8. P. 239. https://pubmed.ncbi.nlm.nih.gov/33674256.
  65. Sliwinski J.R., Johnson A.K., Elkins G.R. Memory decline in peri- and post-menopausal women: the potential of mind-body medicine to improve cognitive performance // Integr. Med. Insights. 2014. Vol. 9. P. 17–23. DOI: 10.4137/IMI.S15682.
  66. Mitchell E.S., Woods N.F. Cognitive symptoms during the menopausal transition and early postmenopause // Climacteric. 2011. Vol. 14. P. 252–261.
  67. Drogos L.L., Rubin L.H., Geller S.E. et al. Objective cognitive performance is related to subjective memory complaints in midlife women with moderate to severe vasomotor symptoms // Menopause. 2013. Vol. 20. P. 1236–1242.
  68. Гвоздев М.Ю. Рецидивные формы недержания мочи // Экспериментальная
    и клиническая урология. 2014. № 3. C. 80–87.
  69. Gubbiotti et al. The impact of Mirabegron on sexual function in women with idiopathic overactive bladder // BMC Urology. 2019. Vol. 19. P. 7. DOI: 10.1186/s12894-019-0438-8.

Для продолжения работы требуется вход / регистрация